C O M P A N Y A N N O U N C E M E N T
Appendix 4C and Activity Report
CLINUVEL REPORTS HIGHEST ANNUAL ROLLING CASH RECEIPTS
ASX: | CUV |
XETRA-DAX: | UR9 |
NASDAQ INTERNATIONAL | CLVLY |
DESIGNATION: |
CLINUVEL PHARMACEUTICALS LTD today announced | KEY CASH FLOW HIGHLIGHTS Q2 FY21: | ||
its Appendix 4C - Quarterly Cashflow Report and | |||
Activity Report for the period 01 October to 31 | |||
December 2020. All figures are rounded and reported in | |||
Australian dollars. |
OPERATING CONDITIONS AND THE GLOBAL ECONOMY
COMMENTARY
Graph 1: Annual Cash Receipts and
Operating Expenditures
(A$m, on rolling quarterly basis)
Cash Receipts | Operating Payments | ||
35.0 | |||
30.0 | |||
25.0 | |||
20.0 | |||
15.0 | |||
10.0 | |||
5.0 | |||
0.0 | |||
Jun-17 | Jun-18 | Jun-19 | Jun-20 |
"The continued performance of the Group stems from our measured strategy, consistent execution, and treatment demand from both the USA and Europe, which have contributed to a new high in annual cash receipts," CLINUVEL's Chief Financial Officer, Mr Darren Keamy said.
"Against the ongoing backdrop of economic uncertainty, and in a quarter where cash receipts are historically lower, reflecting the seasonal demand, we have now been able to deliver a positive net cash result in the December quarter, the first since 2017.
C O M P A N Y A N N O U N C E M E N T
"As of today, CLINUVEL is in a good position to pursue further investments in its R&D and clinical programs, aiming to deliver long-term value while building out the CLINUVEL Group of companies," Mr Keamy said.
STRONG CASH RECEIPTS AND NET CASH
ANNUAL TREND IN CASH RECEIPTS AND EXPENDITURES
CONTROLLED GROWTH IN EXPENDITURES
REVIEW OF KEY ACTIVITIES
•
•
•
C O M P A N Y A N N O U N C E M E N T
•
About CLINUVEL PHARMACEUTICALS LIMITED
Head of Investor Relations
Investor Enquiries
Forward-Looking Statements
C O M P A N Y A N N O U N C E M E N T
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Clinuvel Pharmaceuticals Limited published this content on 28 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 January 2021 22:15:08 UTC.